New treatment option for non-Hodgkin lymphomaradiotherapyrectal neoplasmscombined modality therapytreatment outcomeNew treatment option for non-Hodgkin lymphoma. By - Barbara Boughtondoi:10.1016/S1470-2045(02)00637-XBarbara BoughtonElsevier Ltd.Lancet Oncology...
Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Novelli S; Sierra J; Briones J.New therapies in non- Hodgkin lymphoma.Expert Rev Antieancer Ther.2015.349-359Silvana Novelli, Jorge Sierra, Javier Briones. (2015) New therapies in non-Hodgkin lymphoma. Expert Review of Anticancer Therapy 15 , 349-359 /...
In a startling video released on Friday, veteran YouTube personality Hank Green told his three million subscribers that he has Hodgkin’s lymphoma.Green has been around since YouTube’s early days, active since 2007. He also hosts podcasts with his brother John Green, author of “The Fault ...
Although enormous progress has been made in treating non-Hodgkin's lymphoma (NHL), and some patients can be cured with combination immunochemotherapy, patients with relapsed and refractory lymphoma often succumb to their disease. Advances in our understanding of lymphoma biology and molecular pathogenesi...
The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.
The excellent results obtained with the BEACOPP principle challenge the seemingly global consensus that ABVD is the gold standard treatment strategy for advanced stage HL. 展开 关键词: Hodgkin's lymphoma BEACOPP Chemotherapy treatment Advanced stage....
Moreover, EBV was present in the blood system’s tumour cells, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, and some natural killer (NK) and T cell lymphomas.126 Human endogenous retroviruses (HERVs) have been found in chronic lymphocytic leukaemia, where ERV1 was strongly expressed....
In 1992, the German Hodgkin Study Group (GHSG) developed the BEACOPP regimen for further improving the outcome of patients with advanced Hodgkin's lymphoma (HL). Since then, BEACOPP has been introduced in 3 different prospective randomized clinical trials of the GHSG to find an equilibrium betwe...
Callander noted how CAR-T cell therapies and bispecific engagers have revolutionized the treatment for patients with multiple myeloma who have received multiple prior lines of therapy, which are most commonly used in lymphoma. For multiple myeloma, the target for bispecifics is the B cell maturation...